Abstract
Objectives. This review is to inform clinicians of currently available data on vilazodone for treating patients with major depressive disorder (MDD), focusing on its diff erential action mechanism and extended clinical utility. Methods. A data search was conducted in June 2012 using the PubMed/MEDLINE/ relevant clinical trial databases with the key terms "vilazodone" or "Viibryd." Results. The effi cacy, safety, and tolerability of vilazodone have been demonstrated in two pivotal 8-week, randomized, double-blinded, placebo-controlled studies. Certain pharmacological characteristics of vilazodone were observed, including early onset of action, fewer sexual side eff ects, the absence of known cardiac toxicity, and minimal eff ect on weight gain, that may provide potential clinical advantages compared with currently available antidepressants. However, such possibilities should be replicated and confirmed in more well-designed and adequately powered clinical trials. Vilazodone requires dose titration up to 2 weeks to reach a target dose of 40 mg/d due to high rate of gastrointestinal side eff ects. No direct comparative studies with other antidepressants are currently available to confi rm the aforementioned potential clinical utility. Conclusion. Vilazodone is a newer antidepressant possessing diff erent action mechanisms compared to currently available antidepressants but whether it has superiority to other class of antidepressants in terms of effi cacy and safety should still warrant further evaluation through more well-controlled and direct comparison clinical trials.
| Original language | English |
|---|---|
| Pages (from-to) | 160-169 |
| Number of pages | 10 |
| Journal | International Journal of Psychiatry in Clinical Practice |
| Volume | 17 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2013 Jan 1 |
Fingerprint
Keywords
- Action mechanism
- Antidepressant
- Major depressive disorder
- Vilazodone
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
A review of current evidence for vilazodone in major depressive disorder. / Wang, Sheng Min; Han, Changsu; Lee, Soo Jung; Patkar, Ashwin A.; Masand, Prakash S.; Pae, Chi Un.
In: International Journal of Psychiatry in Clinical Practice, Vol. 17, No. 3, 01.01.2013, p. 160-169.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A review of current evidence for vilazodone in major depressive disorder
AU - Wang, Sheng Min
AU - Han, Changsu
AU - Lee, Soo Jung
AU - Patkar, Ashwin A.
AU - Masand, Prakash S.
AU - Pae, Chi Un
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Objectives. This review is to inform clinicians of currently available data on vilazodone for treating patients with major depressive disorder (MDD), focusing on its diff erential action mechanism and extended clinical utility. Methods. A data search was conducted in June 2012 using the PubMed/MEDLINE/ relevant clinical trial databases with the key terms "vilazodone" or "Viibryd." Results. The effi cacy, safety, and tolerability of vilazodone have been demonstrated in two pivotal 8-week, randomized, double-blinded, placebo-controlled studies. Certain pharmacological characteristics of vilazodone were observed, including early onset of action, fewer sexual side eff ects, the absence of known cardiac toxicity, and minimal eff ect on weight gain, that may provide potential clinical advantages compared with currently available antidepressants. However, such possibilities should be replicated and confirmed in more well-designed and adequately powered clinical trials. Vilazodone requires dose titration up to 2 weeks to reach a target dose of 40 mg/d due to high rate of gastrointestinal side eff ects. No direct comparative studies with other antidepressants are currently available to confi rm the aforementioned potential clinical utility. Conclusion. Vilazodone is a newer antidepressant possessing diff erent action mechanisms compared to currently available antidepressants but whether it has superiority to other class of antidepressants in terms of effi cacy and safety should still warrant further evaluation through more well-controlled and direct comparison clinical trials.
AB - Objectives. This review is to inform clinicians of currently available data on vilazodone for treating patients with major depressive disorder (MDD), focusing on its diff erential action mechanism and extended clinical utility. Methods. A data search was conducted in June 2012 using the PubMed/MEDLINE/ relevant clinical trial databases with the key terms "vilazodone" or "Viibryd." Results. The effi cacy, safety, and tolerability of vilazodone have been demonstrated in two pivotal 8-week, randomized, double-blinded, placebo-controlled studies. Certain pharmacological characteristics of vilazodone were observed, including early onset of action, fewer sexual side eff ects, the absence of known cardiac toxicity, and minimal eff ect on weight gain, that may provide potential clinical advantages compared with currently available antidepressants. However, such possibilities should be replicated and confirmed in more well-designed and adequately powered clinical trials. Vilazodone requires dose titration up to 2 weeks to reach a target dose of 40 mg/d due to high rate of gastrointestinal side eff ects. No direct comparative studies with other antidepressants are currently available to confi rm the aforementioned potential clinical utility. Conclusion. Vilazodone is a newer antidepressant possessing diff erent action mechanisms compared to currently available antidepressants but whether it has superiority to other class of antidepressants in terms of effi cacy and safety should still warrant further evaluation through more well-controlled and direct comparison clinical trials.
KW - Action mechanism
KW - Antidepressant
KW - Major depressive disorder
KW - Vilazodone
UR - http://www.scopus.com/inward/record.url?scp=84883186520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883186520&partnerID=8YFLogxK
U2 - 10.3109/13651501.2013.794245
DO - 10.3109/13651501.2013.794245
M3 - Article
C2 - 23578403
AN - SCOPUS:84883186520
VL - 17
SP - 160
EP - 169
JO - International Journal of Psychiatry in Clinical Practice
JF - International Journal of Psychiatry in Clinical Practice
SN - 1365-1501
IS - 3
ER -